Cancerorp launches new prenatal and postnatal genome testing service 'GenomeCheck'..."Expanding sales channels"

[Asia Economy Reporter Hyunseok Yoo] Cancerop, a global precision medicine company based on molecular diagnostics, announced on the 12th that it will newly launch the genome diagnostic service for prenatal, postnatal, and adult subjects called ‘GenomeCheck’ on the 1st of next month.

Based on its competitiveness as the number one domestic genome testing company, Cancerop will change the name of its testing service to ‘GenomeCheck’ and expand its sales channels to provide even more advanced genome testing services.

The exclusive contract with Boryung Biopharma, which was the previous sales agency partner, will be terminated as of the 31st. The company plans to expand its sales channels to various specialized domestic contract organizations.

A Cancerop representative said, “Only the name of the testing service and sales channels are changing, but the same testing service as before will be provided,” adding, “Through the new sales channels with leading domestic specialized contract organizations, we will provide safer and enhanced services in specimen management and more.”

He continued, “We are promoting the launch of ‘GenomeCheck’ not only domestically but also overseas through collaboration with contract testing organizations,” and stated, “Together with overseas partners secured through sales of COVID-19 diagnostic kits, we are reviewing business feasibility in about 10 countries.”

Cancerop was the first in Korea to develop various genome testing services for prenatal and postnatal stages, providing services such as G-Scanning, G-Scanning Plus, The Mom Scanning, and The Mom Scanning Plus.

Having performed more than 400,000 clinical genome analyses including CMA (Chromosomal MicroArray) and NGS (Next Generation Sequencing) testing services, Cancerop has built the largest genome analysis database in Korea and has published dozens of domestic and international academic papers and filed patents related to this field.

The new brand name ‘GenomeCheck’ attaches letters such as G and M to the main brand name ‘GenomeCheck’ to indicate the purpose of the test. The existing G-Scanning service has been reorganized as an individual brand called ‘GenomeCheck G’, and The Mom Scanning as ‘GenomeCheck M’.

The postnatal test service ‘GenomeCheck G’ is a test that analyzes chromosomal abnormalities in newborns and children using clinical genome analysis CMA, allowing the identification of various congenital malformations or chromosomal abnormality diseases caused by numerical or structural chromosomal abnormalities.

Also, the prenatal test ‘GenomeCheck M’ is a non-invasive test that analyzes cell-free fetal DNA present in the blood of pregnant women using NGS to detect numerical abnormalities in up to 123 chromosomes.